The latest announcements from JelikaLite, a medical technology company with focus on pediatric neurological health using non-invasive novel therapies.

JelikaLite is partnering with GoMo Health, for distribution of Cognilum treatment through national health care providers and Medicaid Managed Care Organizations throughout the U.S.. GoMo Health, a patient and consumer engagement company, works with providers, plans, employers, and pharma companies to improve engagement and patient outcomes across the world. GoMo Health has a growing Pediatric Autism program, making JelikaLite an ideal synergetic partner.  On an annual basis, GoMo Health engages with over 8 million patients and members every day, focusing on serving economically disadvantaged communities worldwide.

In April 2023, JelikaLite together with SUNY Upstate Medical University, received a Jeff Lawrence Innovation Fund Manufacturing Grant of $50,000. The funds will be used by SUNY Upstate Medical University to conduct a new double-blind clinical trial using Cognilum treatment. 

Dr. Eugenia Steingold and Katya Sverdlov presented  the results of our current transcranial photobiomodulation study for treatment of autism in young children at the Synchrony 2022 conference. JelikaLite unveiled new findings from our open label study of a wearable transcranial photobiomodulation device (tPBM) to treat symptoms of autism.

JelikaLite was awarded a National Science Foundation grant SBIR Phase 1: “EEG-guided intelligent transcranial photobiomodulation to reduce symptoms of autism”.   This new $256K grant will allow us to continue developing Cognilum, an intelligent non-invasive therapeutic personalized medical device, designed to be easily administered in the child’s home.  This data-device modality could be disruptive in the Autism treatment standard of care. 

We are delighted to announce that JelikaLite has been chosen as one of 6 companies to present at the second annual Princeton Women Founders Startup Showcase on January 27, 2022

BioWorld highlights JelikaLite’s breakthrough device designation status from the FDA in their featured article.

JelikaLite has been granted Breakthrough Device Designation from the FDA for our Cognilum System – an individualized, non-invasive, investigational technology for the reduction of symptoms of moderate to severe autism spectrum disorder in pediatric patients.

JelikaLite’s StartEngine campaign is live! Since launching our campaign, our team has been blown away by the positive response we’ve received from our community. We are proud of our vision to revolutionalize the pediatric autism treatment and improve the lives of millions of families. We’re so excited to have you on this journey with us.